TrialCancer2019

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Robert Haddad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.